Find any stock by ticker or company name
Barcha huquqlar himoyalangan.
15.05
0.00 (0.00%)
Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.
– Agreement supports commitment to patient access, affordability and innovation – TOKYO, Aug. 31, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has reached an agreement with the U.S. government that reflects our commitment to patient access, affordability and innovation, while reinforcing Astellas' longstanding commitment to the U.S. healthcare system. Under the agreement, Astellas will take the following actions: Lower the prices of medicines in Medicaid and establish pricing for future medicines aligned with other developed nations that reflect international market conditions, innovation, and patient value.
The agreements provide for all state Medicaid programs to pay prices for prescription drugs that match the lowest prices paid by other developed nations, the White House said
ASEKY, ALPMY and ATS have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2026.
The portfolio outperformed the MSCI EAFE benchmark in the second quarter of 2026. Contributors include Infineon Technologies, Tokyo Electron and Recruit Holdings. Detractors include Murata Manufacturing, SoftBank Group and Astellas Pharma.
COIN, ALPMY and MUX have been added to the Zacks Rank #5 (Strong Sell) List on August 6th, 2026.
There is no data to display
